Ascendis Pharma A/S

ASND Healthcare Biotechnology

Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.

Revenue
+119.9%
EPS
+612.3%
Free cash flow
+2,335.9%
Total debt
−41.8%

Quarter to June 2026, against a year earlier

256.42 2.97 +1.17%
Market cap
$16.6B
P/E
18.3×
Fwd P/E
15.4×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.51
Dividend safety
n/a

Ascendis Pharma A/S (ASND) Net margin

Alert me on Net margin

Ascendis Pharma A/S's net margin over the twelve months to 30 June 2026 was 71.2%, up 102.9 percentage points from fiscal 2025 (−31.7%). Over the past ten years it has ranged from −8,097.7% (fiscal 2017) to −31.7% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −31.7% 72.30
FY2024 −104.0% 76.54
FY2023 −180.5% 959.12
FY2022 −1,139.6% 3,791.91
FY2021 −4,931.5% 1,094.00
FY2020 −6,025.5% (4,395.51)
FY2019 −1,630.0% (400.50)
FY2018 −1,229.5% 6,868.12
FY2017 −8,097.7% (6,610.35)
FY2016 −1,487.3% (1,081.76)

Quarterly newest first

Period Net margin Change (points)
Jun 2026 61.0% (194.21)
Mar 2026 255.2% 270.58
Dec 2025 −15.4% 13.18
Sep 2025 −28.6% (3.97)
42 more quarters

Against its own ten years

Low −8,097.7% High −31.7%
Ten-year median −1,229.5%
Current reading's percentile 100

Net margin against peers

Company Net margin
ASND Ascendis Pharma A/S 71.2%
ALNY Alnylam Pharmaceuticals, Inc. compare 52.9%
EXEL Exelixis, Inc. compare 35.5%
HALO Halozyme Therapeutics, Inc. compare 26.9%
JAZZ Jazz Pharmaceuticals PLC compare 4.37%
SMMT Summit Therapeutics PLC compare 0.00%
INSM Insmed, Inc. compare −39.9%
BBIO BridgeBio Pharma, Inc. compare −62.6%
BNTX BioNTech SE Sponsored ADR compare −63.8%
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 1.06%

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on ASND